TIDMCOG

RNS Number : 1986Q

Cambridge Cognition Holdings PLC

26 October 2021

Cambridge Cognition Holdings Plc

   (" Cambridge Cognition"   or the "Company")

Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer. Cambridge Cognition has been selected again to provide its proprietary gold standard digital cognitive assessments, CANTAB (TM) , and specialist study management services. The latest contract is worth more than GBP600,000 to the Company over three years.

Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. CANTAB (TM) cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future."

For further information, contact:

 
 Cambridge Cognition Holdings Plc              Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer        press@camcog.com 
  Michael Holton, Chief Financial Officer 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: 020 7220 0500 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane / Charlotte Sutcliffe              (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)        Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTEAXESASXFFFA

(END) Dow Jones Newswires

October 26, 2021 02:00 ET (06:00 GMT)

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Cambridge Cognition.
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Cambridge Cognition.